Mersana TherapeuticsMRSN
About: Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
Employees: 123
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
25% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 36
19% more call options, than puts
Call options by funds: $1.5M | Put options by funds: $1.26M
3% less funds holding
Funds holding: 125 [Q1] → 121 (-4) [Q2]
5.95% less ownership
Funds ownership: 99.29% [Q1] → 93.34% (-5.95%) [Q2]
18% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 22
50% less funds holding in top 10
Funds holding in top 10: 2 [Q1] → 1 (-1) [Q2]
57% less capital invested
Capital invested by funds: $540M [Q1] → $230M (-$310M) [Q2]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Citigroup Ashiq Mubarack 33% 1-year accuracy 1 / 3 met price target | 150%upside $5 | Buy Maintained | 27 Aug 2024 |
Baird Colleen Kusy 20% 1-year accuracy 3 / 15 met price target | 50%upside $3 | Neutral Maintained | 14 Aug 2024 |
